Asthma and atopy in COVID-19: 2021 updates - 03/02/22
Doi : 10.1016/j.jaci.2021.12.762
Tara F. Carr, MD ⁎ 
, Monica Kraft, MD
, Monica Kraft, MD Asthma and Airway Disease Research Center, Department of Medicine, University of Arizona, Tucson, Ariz
∗Corresponding author: Tara F. Carr, MD, 1501 N Campbell Ave, Tucson, AZ 85724-5030.1501 N Campbell AveTucsonAZ85724-5030
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Key words : Asthma, COVID-19 disease, SARS-CoV-2, atopy
Il testo completo di questo articolo è disponibile in PDF.
Mappa
| Supported by grants from the National Institutes of Health and the American Lung Association. |
|
| Disclosure of potential conflict of interest: T. F. Carr reports consulting fees from AstraZeneca, Genentech, Novartis, GSK; speaker fees from Regeneron, AstraZeneca, and Novartis; and editorial fees from UpToDate. M. Kraft reports research grants from AstraZeneca and Sanofi-Regeneron, NIH and American Lung Association paid to the University of Arizona; consulting fees from Chiesi, Astra-Zeneca, Genentech, and Sanofi-Regeneron; speaker fees from Chiesi; patents for RaeSedo, LLC, and is company founder and Chief Medical Officer; and editorial fees from UpToDate. |
© 2021
Pubblicato da Elsevier Masson SAS.
Vol 149 - N° 2
P. 562-564 - Febbraio 2022 Ritorno al numero
Articolo precedente
- Treatment of chronic or relapsing COVID-19 in immunodeficiency
- Li-An K. Brown, Ed Moran, Anna Goodman, Helen Baxendale, William Bermingham, Matthew Buckland, Iman AbdulKhaliq, Hannah Jarvis, Michael Hunter, Surendra Karanam, Aisha Patel, Megan Jenkins, Alexander Robbins, Sujoy Khan, Thomas Simpson, Stephen Jolles, Jonathan Underwood, Sinisa Savic, Alex Richter, Adrian Shields, Michael Brown, David M. Lowe
- Immune health grades: Finding resilience in the COVID-19 pandemic and beyond
- Vincent C. Marconi, Venkatesh Krishnan, E. Wesley Ely, Monty Montano
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.